Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Approaches to the safety assessment of engineered nanomaterials (ENM) in food.
Cockburn A, Bradford R, Buck N, Constable A, Edwards G, Haber B, Hepburn P, Howlett J, Kampers F, Klein C, Radomski M, Stamm H, Wijnhoven S, Wildemann T. Cockburn A, et al. Among authors: haber b. Food Chem Toxicol. 2012 Jun;50(6):2224-42. doi: 10.1016/j.fct.2011.12.029. Epub 2011 Dec 29. Food Chem Toxicol. 2012. PMID: 22245376 Review.
Long-term storage of unamplified complete PCR mixtures.
Reischl U, Haber B, Vandezande W, De Baere T, Vaneechoutte M. Reischl U, et al. Among authors: haber b. Biotechniques. 1997 Oct;23(4):580-2, 584. doi: 10.2144/97234bm03. Biotechniques. 1997. PMID: 9343665 Free article. No abstract available.
Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients.
Groll AH, Schulte JH, Antmen AB, Fraser CJ, Teal VL, Haber B, Caro L, McCrea JB, Fancourt C, Patel M, Menzel K, Badshah C. Groll AH, et al. Among authors: haber b. Pediatr Infect Dis J. 2024 Mar 1;43(3):203-208. doi: 10.1097/INF.0000000000004208. Epub 2024 Jan 19. Pediatr Infect Dis J. 2024. PMID: 38241643 Clinical Trial.
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Russo D, Schmitt M, Pilorge S, Stelljes M, Kawakita T, Teal VL, Haber B, Bopp C, Dadwal SS, Badshah C. Russo D, et al. Among authors: haber b. Lancet Haematol. 2024 Feb;11(2):e127-e135. doi: 10.1016/S2352-3026(23)00344-7. Epub 2023 Dec 21. Lancet Haematol. 2024. PMID: 38142695 Clinical Trial.
169 results